| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5594337 | American Heart Journal | 2017 | 30 Pages |
Abstract
Fibrinolysis-treated STEMI patients who received clopidogrel and aspirin at the time of fibrinolysis and were undergoing early PCI frequently had PRU >208. In this high-risk population, ticagrelor provides more prompt and potent platelet inhibition compared with clopidogrel (Funded by Astra Zeneca; NCT01930591, https://clinicaltrials.gov/ct2/show/NCT01930591).
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Payam MD, Andrea MD, Shahar MD, Jennifer J. PhD, Sebastian PhD, Rodney H. MD, Jeff MD, Sheila MSc, Warren J. MD, Shamir R. MD, Akshay MD, Shaun G. MD, MSc, Asim N. MD, PhD,